Gensight biologics market cap
WebGenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. Use the CB Insights Platform to explore GenSight Biologics's full profile. ... Market Cap 0.17B. WebApr 4, 2024 · GenSight Biologics saw a decline in short interest in February. As of February 15th, there was short interest totaling 10,200 shares, a decline of 2.9% from the previous total of 10,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price ...
Gensight biologics market cap
Did you know?
WebFeb 27, 2024 · GenSight Biologics has 5 employees across 3 locations and €5.28 m in annual revenue in FY 2024. See insights on GenSight Biologics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. ... Market Capitalization. €145.9 M. 2024-02-27. Revenue. €5.3 M. FY, 2024. GenSight … WebFind the latest GenSight Biologics S.A. (GSGTF) stock quote, history, news and other vital information to help you with your stock trading and investing.
WebGenSight Biologics – Leader in Gene Therapy Against Blindness Advancing gene therapy for neurodegenerative ophthalmic diseases We are developing therapies to preserve or … WebGenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
WebApr 10, 2024 · GenSight Biologics SA is a clinical-stage gene therapy company. It is engaged in research and development of novel therapies for mitochondrial and … WebGENSIGHT BIOLOGICS Inc. 3 East 28th Street New York, NY 10016 USA
WebSIGHT — Gensight Biologics SA Share Price. €3.54 0.00 0.00%. Last trade - 00:00. Healthcare Highly Speculative Small Cap Momentum Trap. Market Cap. €163.84m. Enterprise Value. €155.79m. Revenue.
WebThe average market cap of companies in the sector is 192.3 M with a standard deviation of 297.2 M. GenSight Biologics S.A.'s Market Cap of 178.9 M ranks in the 70.9% … how does luno threaten noah and abbeyWebOur strategic vision is to become the leader in gene therapy for ophthalmology diseases. We aim at building a fully integrated company that could ultimately be either developed as a specialty business after being listed on a European stock exchange or acquired by a large pharmaceutical company. Vision loss is the most feared consequence of … how does lung cancer pain feelWebGenSight Biologics S.A. (SIGHT.PA) Paris - Paris Delayed Price. Currency in EUR Follow 2.3000 -0.0250 (-1.08%) At close: 05:39PM CEST 1d 5d 1m 6m YTD 1y 5y Max Full screen Gain actionable... Find out all the key statistics for GenSight Biologics S.A. (SIGHT.PA), including … Stocks sink after Fed minutes despite cooler inflation: Stock market news … GenSight Biologics to Present at Upcoming Medical Conferences. PARIS, March 10, … Find the latest GenSight Biologics S.A. (SIGHT.PA) stock discussion in Yahoo … photo of crazy horse memorialWebMarket Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible … how does lung cancer affect your lungsWebFeb 2, 2024 · This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company"), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. ... Euronext Listed SIGHT / €165m Market Cap / Avg. 30-day Daily … how does lung cancer metastasisWebDec 31, 2024 · GenSight Biologics S.A. has completed an IPO in the amount of €40 million. GenSight Biologics S.A. has completed an IPO in the amount of €40 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,000,000 PriceRange: €8 Transaction Features: Regulation S; Rule 144A; Sponsor … how does lung cancer beginWebApr 8, 2024 · Cash and cash equivalents totaled €44.3 million as of December 31, 2024, compared to €37.9 million as of December 31, 2024. The amounts of expected future cash flows related to the reimbursement of our financial debts were €4.6 million at less than one year and €12.4 million at more than one year. GenSight Biologics will report its cash ... photo of crossroads